Advanced search
Publication Cover
Leukemia & Lymphoma Volume 49, 2008 - Issue 8
Submit an article Journal homepage
189
Views
11
CrossRef citations to date
0
Altmetric
Reviews

Treatment of relapsed and refractory myeloma

Donna E. Reece Program for Multiple Myeloma and Related Diseases, Princess Margaret Hospital, Toronto, Ontario, CanadaCorrespondence[email protected]
,
Heather A. Leitch Division of Hematology, St. Paul's Hospital and the University of British Columbia, Vancouver, British Columbia, Canada
,
Harold Atkins The Ottawa Hospital Blood and Marrow Transplant Program, Ottawa, Ontario, Canada
,
Michael Voralia Hematology/Stem Cell Transplant Program, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
,
Leah A. Canning Kaleidoscope Strategic, Toronto, Ontario, Canada
,
Richard LeBlanc Centre Hospitalier Universitaire de Quèbec, Quèbec, Canada
,
Andrew R. Belch Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
,
Darrell White Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada
&
Michael J. Kovacs London Health Sciences Centre, University of Western Ontario, London, Ontario, Canada
 show all
Pages 1470-1485 | Received 15 Jan 2008, Accepted 15 Mar 2008, Published online: 01 Jul 2009

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Bahman Razi, Gholamreza Anani Sarab, Azadeh Omidkhoda & Shahab Alizadeh. (2018) Multidrug resistance 1 (MDR1/ABCB1) gene polymorphism (rs1045642 C > T) and susceptibility to multiple myeloma: a systematic review and meta-analysis. Hematology 23:8, pages 456-462.
Read now
Anne-Marie Ronchetti, Françoise Isnard, Marc Buffet, Tereza Coman, Norbert-Claude Gorin, Paul Coppo, Laurent Garderet & Sandra Malak. (2013) Dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) is an effective salvage regimen for multiple myeloma refractory to novel agents. Leukemia & Lymphoma 54:5, pages 1117-1119.
Read now

Articles from other publishers (9)

Enrique M. Ocio, Carmen Montes-Gaisán, Gabriela Bustamante, Sebastián Garzón, Esther González, Ernesto Pérez, Maialen Sirvent, José María Arguiñano, Yolanda González, Rafael Ríos, Dunia de Miguel, Marta Grande, Alonso Fernández, Andrea Naves & Laura Rosiñol. (2022) Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study. Clinical Lymphoma Myeloma and Leukemia 22:4, pages e241-e249.
Crossref
Masanobu Tsubaki, Tomoya Takeda, Naoki Ogawa, Kotaro Sakamoto, Hirotaka Shimaoka, Arisa Fujita, Tatsuki Itoh, Motohiro Imano, Toshihiko Ishizaka, Takao Satou & Shozo Nishida. (2015) Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells. Leukemia Research 39:4, pages 445-452.
Crossref
Djordje Atanackovic & Georgia Schilling. (2013) Second autologous transplant as salvage therapy in multiple myeloma. British Journal of Haematology 163:5, pages 565-572.
Crossref
Masanobu Tsubaki, Takao Satou, Tatsuki Itoh, Motohiro Imano, Makiko Komai, Minori Nishinobo, Megumi Yamashita, Masashi Yanae, Yuzuru Yamazoe & Shozo Nishida. (2012) Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells. Leukemia Research 36:10, pages 1315-1322.
Crossref
Gabriele Buda, Deborah Ricci, C. Chris Huang, Reyna Favis, Nadine Cohen, Sen H. Zhuang, Jean-Luc Harousseau, Pieter Sonneveld, Joan Bladé & Robert Z. Orlowski. (2010) Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Annals of Hematology 89:11, pages 1133-1140.
Crossref
Sundar Jagannath, Meletios A. Dimopoulos & Sagar Lonial. (2010) Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. Leukemia Research 34:9, pages 1111-1118.
Crossref
Tiffany Richards & Donna Weber. (2010) Advances in treatment for relapses and refractory multiple myeloma. Medical Oncology 27:S1, pages 25-42.
Crossref
Sheeba K. Thomas, Tiffany A. Richards & Donna M. Weber. (2009) Novel Agents for Relapsed and/or Refractory Multiple Myeloma. The Cancer Journal 15:6, pages 485-493.
Crossref
Michael Groll, Robert Huber & Luis Moroder. (2009) The persisting challenge of selective and specific proteasome inhibition. Journal of Peptide Science 15:2, pages 58-66.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.